Steven W. Elmore
57Patents
20h-index
77Co-inventors
91Inventor score
Filing activity: Jun 5, 1995 → Oct 7, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7390799B2 | Apoptosis promoters | Chemistry; Metallurgy | 197 | Active |
| US7767684B2 | Apoptosis promoters | Chemistry; Metallurgy | 87 | Active |
| US8563735B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 70 | Active |
| US7642260B2 | Apoptosis promoters | Chemistry; Metallurgy | 60 | Active |
| US8546399B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 57 | Active |
| US8586754B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 55 | Active |
| US7973161B2 | Apoptosis promoters | Chemistry; Metallurgy | 50 | Active |
| US8426422B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 47 | Active |
| US7842681B2 | Treatment of myeoproliferative diseases | Human Necessities | 47 | Active |
| US8173811B2 | Apoptosis promoters | Chemistry; Metallurgy | 42 | Active |
| US8114893B2 | Compounds and methods of use | Chemistry; Metallurgy | 42 | Active |
| US8084607B2 | Apoptosis promoters | Chemistry; Metallurgy | 37 | Active |
| US8580794B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 35 | Active |
| US8614318B2 | Apoptosis promoters | Chemistry; Metallurgy | 35 | Active |
| US7709467B2 | Apoptosis promoters | Chemistry; Metallurgy | 35 | Active |
| US6506766B1 | Glucocortiocoid-selective antinflammatory agents | Human Necessities | 34 | Expired |
| US8354404B2 | Apoptosis promoters | Chemistry; Metallurgy | 33 | Active |
| US8343967B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 32 | Active |
| US8518970B2 | Compounds and methods of use | Chemistry; Metallurgy | 28 | Active |
| US8232273B2 | Heterocyclic compounds and methods of use | Chemistry; Metallurgy | 26 | Active |
| US8952157B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 19 | Active |
| US9029404B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 16 | Active |
| US9034875B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 16 | Active |
| US5597823A | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists | Chemistry; Metallurgy | 16 | Expired |
| US9174982B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 15 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.